Business Wire

INCOGNITO-SOFTWARE

14.3.2022 14:02:05 CET | Business Wire | Press release

Share
Optima Italia Deploys Incognito’s Digital Experience Solution to Support Network Growth

Incognito Software Systems Inc. , a leading global provider of broadband service orchestration software solutions for digital service providers, announces that Optima Italia S.p.A. has gone live with Incognito’s Digital Experience (DX) Solution to streamline and improve the customer experience. With Incognito, Optima can centralize and streamline the management of all devices in its network to deliver an uninterrupted, high-quality customer experience using a carrier-grade solution that can scale with their network and service growth.

As a leading Italian digital company service provider, Optima offers an integrated collection of services, including electricity, gas, mobile, and Internet for business and residential markets. To support a significant and growing customer base across major centers, Optima required a solution to scale operations by replacing time- and labor-intensive manual processes with an industry awarded platform. Underpinned by Incognito’s fully featured Broadband Forum-compliant Auto Configuration Server (ACS) , the Digital Experience smart platform automates the resolution of technical issues that impact service quality.

Optima selected Incognito to support them in their automation efforts based on Incognito’s expertise enhancing subscriber experience, reducing operational costs, and supporting the delivery of innovative services into the connected home. “It was quickly apparent that Incognito could offer a great platform implementation, with system go-live in a matter of weeks,” said Paolo Primiani, Network & Voice engineer at Optima Italia.

“We are very proud to be working with Optima Italia as a technology partner for their rollout of high-speed fiber broadband services to customers across its service areas,” said Ricardo Gonzalez, VP of Sales at Incognito. “Optima is one of the leading broadband providers in Italy, respected for their dedication to customer experience. Our mission is to provide telecom operators with tools that help them increase efficiency while reducing costs, and we look forward to contributing to Optima’s success.”

The Digital Experience Solution (DX) is an industry awarded platform, used around the world by premier broadband service providers to manage and orchestrate internet of things (IoT) and customer premise equipment (CPE) with Broadband Forum’s TR-069, User Services Platform (USP / TR-369) , and other management protocols. To learn more about Digital Experience Solution and Incognito’s suite of orchestration solutions, visit www.incognito.com .

About Incognito

Incognito Software Systems Inc. provides service orchestration software and services that help digital service providers manage the next-generation broadband experience. Over 200 customers worldwide, including Claro, Cox, Digicel, Globe, and Orange, leverage Incognito solutions to fast-track the introduction of innovative broadband services over fiber, cable, and fixed wireless technologies, while delivering a great customer experience. The company is a division of the Lumine Group , a portfolio of Constellation Software Inc. , the largest independent software company in Canada. Visit www.incognito.com or follow us on LinkedIn and Twitter .

About Optima Italia

Optima Italia S.p.A., is a leading Italian digital company for the integrated provision of energy (electricity and gas) and telecommunications (internet, telephone, and mobile) services for the business and consumer markets. Optima was founded in 1999 by entrepreneurs Danilo Caruso and Alessio Matrone with the objective of creating a service company to simplify life for families and businesses. Visit www.optimaitalia.com , or follow on LinkedIn .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye